Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Barrett oesophagus.

Peters Y, Al-Kaabi A, Shaheen NJ, Chak A, Blum A, Souza RF, Di Pietro M, Iyer PG, Pech O, Fitzgerald RC, Siersema PD.

Nat Rev Dis Primers. 2019 May 23;5(1):35. doi: 10.1038/s41572-019-0086-z. Review.

PMID:
31123267
2.

Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma.

Fitzgerald RC, Rhodes JM.

Br J Cancer. 2019 Jun;120(12):1099-1104. doi: 10.1038/s41416-019-0467-9. Epub 2019 May 9. Review.

PMID:
31068670
3.

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S, Bower L, Eldridge MD, Devonshire G, Cheah C, Turkington R, Hardwick RH, Selgrad M, Venerito M, Malfertheiner P; OCCAMS Consortium, Fitzgerald RC.

Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32384. [Epub ahead of print]

PMID:
31050820
4.

A clinically translatable hyperspectral endoscopy (HySE) system for imaging the gastrointestinal tract.

Yoon J, Joseph J, Waterhouse DJ, Luthman AS, Gordon GSD, di Pietro M, Januszewicz W, Fitzgerald RC, Bohndiek SE.

Nat Commun. 2019 Apr 23;10(1):1902. doi: 10.1038/s41467-019-09484-4.

5.

A sinister black finding in the stomach.

Januszewicz W, Corrie P, Liu H, Chan J, Fitzgerald RC, di Pietro M.

Lancet. 2019 Mar 16;393(10176):1149. doi: 10.1016/S0140-6736(19)30423-4. Epub 2019 Mar 14. No abstract available.

PMID:
30894270
6.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gut. 2019 Mar 9. pii: gutjnl-2018-317624. doi: 10.1136/gutjnl-2018-317624. [Epub ahead of print]

7.

Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus?

Fitzgerald RC, Corley DA.

Gastroenterology. 2019 Apr;156(5):1228-1231. doi: 10.1053/j.gastro.2019.03.001. Epub 2019 Mar 5. No abstract available.

PMID:
30849313
8.

The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.

Frankell AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, Grehan N, Mok J, O'Donovan M, MacRae S, Eldridge MD, Tavaré S; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Fitzgerald RC.

Nat Genet. 2019 Mar;51(3):506-516. doi: 10.1038/s41588-018-0331-5. Epub 2019 Feb 4.

PMID:
30718927
9.

No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study.

Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study Consortium, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP.

Clin Gastroenterol Hepatol. 2019 Feb 1. pii: S1542-3565(19)30088-6. doi: 10.1016/j.cgh.2019.01.041. [Epub ahead of print]

PMID:
30716477
10.

Early detection and therapeutics.

Januszewicz W, Fitzgerald RC.

Mol Oncol. 2019 Mar;13(3):599-613. doi: 10.1002/1878-0261.12458. Epub 2019 Feb 20. Review.

11.

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Rogerson C, Bleaney CW, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2019 Jan 22;9(1):318. doi: 10.1038/s41598-018-37591-7.

12.

A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.

Duits LC, Lao-Sirieix P, Wolf WA, O'Donovan M, Galeano-Dalmau N, Meijer SL, Offerhaus GJA, Redman J, Crawte J, Zeki S, Pouw RE, Chak A, Shaheen NJ, Bergman JJGHM, Fitzgerald RC.

Dis Esophagus. 2019 Jan 1;32(1). doi: 10.1093/dote/doy102.

PMID:
30496496
13.

Somatic mutant clones colonize the human esophagus with age.

Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, Cagan A, Murai K, Mahbubani K, Stratton MR, Fitzgerald RC, Handford PA, Campbell PJ, Saeb-Parsy K, Jones PH.

Science. 2018 Nov 23;362(6417):911-917. doi: 10.1126/science.aau3879. Epub 2018 Oct 18.

14.

DNA Methylation Biomarkers for the Diagnosis of Barrett's Oesophagus.

Kosmidou C, Jammula S, Fitzgerald RC.

Am J Gastroenterol. 2018 Nov;113(11):1722. doi: 10.1038/s41395-018-0226-1. Epub 2018 Oct 17. No abstract available.

PMID:
30333547
15.

A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge.

Tan WK, Muldrew B, Khan Z, Fitzgerald RC.

Dis Esophagus. 2019 Jan 1;32(1). doi: 10.1093/dote/doy085.

PMID:
30239646
16.

Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.

Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium.

Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27.

17.

Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients.

Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, Kadri S, di Pietro M, Boussioutas A, Shaheen NJ, Katzka DA, Dellon ES, Fitzgerald RC; BEST1 and BEST2 study investigators.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):647-656.e1. doi: 10.1016/j.cgh.2018.07.043. Epub 2018 Aug 9.

18.

MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way.

Smyth EC, Fitzgerald RC.

JAMA Oncol. 2018 Dec 1;4(12):1698-1699. doi: 10.1001/jamaoncol.2018.2803. No abstract available.

19.

Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening.

Sami SS, Iyer PG, Pophali P, Halland M, di Pietro M, Ortiz-Fernandez-Sordo J, White JR, Johnson M, Guha IN, Fitzgerald RC, Ragunath K.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):638-646.e1. doi: 10.1016/j.cgh.2018.07.019. Epub 2018 Aug 3.

20.

Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.

Offman J, Muldrew B, O'Donovan M, Debiram-Beecham I, Pesola F, Kaimi I, Smith SG, Wilson A, Khan Z, Lao-Sirieix P, Aigret B, Walter FM, Rubin G, Morris S, Jackson C, Sasieni P, Fitzgerald RC; BEST3 Trial team.

BMC Cancer. 2018 Aug 3;18(1):784. doi: 10.1186/s12885-018-4664-3.

21.

Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

Li X, Francies HE, Secrier M, Perner J, Miremadi A, Galeano-Dalmau N, Barendt WJ, Letchford L, Leyden GM, Goffin EK, Barthorpe A, Lightfoot H, Chen E, Gilbert J, Noorani A, Devonshire G, Bower L, Grantham A, MacRae S, Grehan N, Wedge DC, Fitzgerald RC, Garnett MJ.

Nat Commun. 2018 Jul 30;9(1):2983. doi: 10.1038/s41467-018-05190-9.

22.

Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?

O'Donovan M, Fitzgerald RC.

Dig Dis Sci. 2018 Aug;63(8):2105-2114. doi: 10.1007/s10620-018-5192-3. Review.

23.

Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus.

Li X, Kleeman S, Coburn SB, Fumagalli C, Perner J, Jammula S, Pfeiffer RM, Orzolek L, Hao H, Taylor PR, Miremadi A, Galeano-Dalmau N, Lao-Sirieix P, Tennyson M, MacRae S, Cook MB, Fitzgerald RC.

Gastroenterology. 2018 Sep;155(3):771-783.e3. doi: 10.1053/j.gastro.2018.05.050. Epub 2018 Jun 12.

24.

Organ-preserving approaches in oesophageal cancer.

Fitzgerald RC.

Lancet Oncol. 2018 Jul;19(7):858-859. doi: 10.1016/S1470-2045(18)30291-2. Epub 2018 Jun 1. No abstract available.

25.

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, Reid NB, Spence VJ, Chisambo C, McManus D, James J, McQuaid S, Craig S, Arthur K, McArt D, Ong CJ, Lao-Sirieix P, Hamilton P, Salto-Tellez M, Eatock M, Coleman HG, Fitzgerald RC, Kennedy RD, Turkington RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Oncotarget. 2018 Apr 6;9(26):18518-18528. doi: 10.18632/oncotarget.24906. eCollection 2018 Apr 6.

26.

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, Brewer C, Davidson R, Ellis I, Evans DG, Halliday D, Izatt L, Marks P, McConnell V, Verbist L, Mayes R, Clark GR, Hadfield J, Chin SF, Teixeira MR, Giger OT, Hardwick R, di Pietro M, O'Donovan M, Pharoah P, Caldas C, Fitzgerald RC, Tischkowitz M.

Lancet Gastroenterol Hepatol. 2018 Jul;3(7):489-498. doi: 10.1016/S2468-1253(18)30079-7. Epub 2018 Apr 27.

27.

New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?

Spechler SJ, Katzka DA, Fitzgerald RC.

Gastroenterology. 2018 May;154(6):1594-1601. doi: 10.1053/j.gastro.2018.03.031. Epub 2018 Mar 23. Review. No abstract available.

PMID:
29577931
28.

Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus.

Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) Consortium, Corley DA, Shaheen NJ, Lagergren J, Hardie LJ, Reid BJ, Iyer PG, Risch HA, Caldas C, Caldas I, Pharoah PD, Liu G, Gammon MD, Chow WH, Bernstein L, Bird NC, Ye W, Wu AH, Anderson LA, MacGregor S, Whiteman DC, Vaughan TL, Thrift AP.

Clin Gastroenterol Hepatol. 2018 Oct;16(10):1598-1606.e4. doi: 10.1016/j.cgh.2018.03.007. Epub 2018 Mar 15.

29.

Detection of early neoplasia in Barrett's esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue.

Neves AA, Di Pietro M, O'Donovan M, Waterhouse DJ, Bohndiek SE, Brindle KM, Fitzgerald RC.

Endoscopy. 2018 Jun;50(6):618-625. doi: 10.1055/s-0043-124080. Epub 2018 Jan 17.

30.

Esophageal Diseases.

Fitzgerald RC, Vaezi MF.

Gastroenterology. 2018 Jan;154(2):263-266. doi: 10.1053/j.gastro.2017.12.017. Epub 2017 Dec 21. No abstract available.

PMID:
29274867
31.

Corrigendum: Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study.

Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, Shaheen NJ, Fitzgerald RC, Dellon ES.

Am J Gastroenterol. 2018 Feb;113(2):310. doi: 10.1038/ajg.2017.474. Epub 2017 Dec 19.

PMID:
29257149
32.

Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP.

Gastroenterology. 2018 Apr;154(5):1273-1281.e3. doi: 10.1053/j.gastro.2017.12.003. Epub 2017 Dec 13.

33.

Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus.

Katz-Summercorn A, Anand S, Ingledew S, Huang Y, Roberts T, Galeano-Dalmau N, O'Donovan M, Liu H, Fitzgerald RC.

J Pathol Clin Res. 2017 Aug 24;3(4):258-267. doi: 10.1002/cjp2.80. eCollection 2017 Oct.

34.

Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.

Chettouh H, Mowforth O, Galeano-Dalmau N, Bezawada N, Ross-Innes C, MacRae S, Debiram-Beecham I, O'Donovan M, Fitzgerald RC.

Gut. 2018 Nov;67(11):1942-1949. doi: 10.1136/gutjnl-2017-314026. Epub 2017 Oct 30.

35.

Early Diagnosis of Gastroesophageal Cancers and the Cytosponge: A Work in Progress.

Fitzgerald RC, Reid BJ.

Cell Mol Gastroenterol Hepatol. 2017 Aug 14;4(3):447. doi: 10.1016/j.jcmgh.2017.07.004. eCollection 2017 Nov. No abstract available.

36.

Cancer development: Origins in the oesophagus.

Zhuang L, Fitzgerald RC.

Nature. 2017 Oct 26;550(7677):463-464. doi: 10.1038/nature24150. Epub 2017 Oct 11. No abstract available.

37.

Corrigendum: A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Genome Res. 2017 Oct;27(10):1782. doi: 10.1101/gr.229153.117. No abstract available.

38.

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Br J Surg. 2017 Dec;104(13):1816-1828. doi: 10.1002/bjs.10627. Epub 2017 Sep 25.

39.

International cancer seminars: a focus on esophageal squamous cell carcinoma.

Murphy G, McCormack V, Abedi-Ardekani B, Arnold M, Camargo MC, Dar NA, Dawsey SM, Etemadi A, Fitzgerald RC, Fleischer DE, Freedman ND, Goldstein AM, Gopal S, Hashemian M, Hu N, Hyland PL, Kaimila B, Kamangar F, Malekzadeh R, Mathew CG, Menya D, Mulima G, Mwachiro MM, Mwasamwaja A, Pritchett N, Qiao YL, Ribeiro-Pinto LF, Ricciardone M, Schüz J, Sitas F, Taylor PR, Van Loon K, Wang SM, Wei WQ, Wild CP, Wu C, Abnet CC, Chanock SJ, Brennan P.

Ann Oncol. 2017 Sep 1;28(9):2086-2093. doi: 10.1093/annonc/mdx279. Review.

40.

Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma.

Britton E, Rogerson C, Mehta S, Li Y, Li X; OCCAMS consortium, Fitzgerald RC, Ang YS, Sharrocks AD.

PLoS Genet. 2017 Aug 31;13(8):e1006879. doi: 10.1371/journal.pgen.1006879. eCollection 2017 Aug.

41.

Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study.

Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, Shaheen NJ, Fitzgerald RC, Dellon ES.

Am J Gastroenterol. 2017 Oct;112(10):1538-1544. doi: 10.1038/ajg.2017.244. Epub 2017 Aug 15. Erratum in: Am J Gastroenterol. 2017 Dec 19;:.

42.

Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy.

di Pietro M, Canto MI, Fitzgerald RC.

Gastroenterology. 2018 Jan;154(2):421-436. doi: 10.1053/j.gastro.2017.07.041. Epub 2017 Aug 2. Review.

43.

Oesophageal cancer.

Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D.

Nat Rev Dis Primers. 2017 Jul 27;3:17048. doi: 10.1038/nrdp.2017.48. Review.

44.

The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma.

Contino G, Vaughan TL, Whiteman D, Fitzgerald RC.

Gastroenterology. 2017 Sep;153(3):657-673.e1. doi: 10.1053/j.gastro.2017.07.007. Epub 2017 Jul 14. Review.

45.

Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.

Ten Kate FJC, van Olphen SH, Bruno MJ, Wijnhoven BPL, van Lanschot JJB, Looijenga LHJ, Fitzgerald RC, Biermann K.

Br J Surg. 2017 Sep;104(10):1327-1337. doi: 10.1002/bjs.10553. Epub 2017 Jul 10.

46.

Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status.

Mi EZ, Mi EZ, di Pietro M, O'Donovan M, Hardwick RH, Richardson S, Ziauddeen H, Fletcher PC, Caldas C, Tischkowitz M, Ragunath K, Fitzgerald RC.

Gastrointest Endosc. 2018 Feb;87(2):408-418. doi: 10.1016/j.gie.2017.06.028. Epub 2017 Jul 6.

47.

Alternatives to Traditional Per-Oral Endoscopy for Screening.

Offman J, Fitzgerald RC.

Gastrointest Endosc Clin N Am. 2017 Jul;27(3):379-396. doi: 10.1016/j.giec.2017.02.002. Epub 2017 Apr 4. Review.

48.

Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis.

Fels Elliott DR, Perner J, Li X, Symmons MF, Verstak B, Eldridge M, Bower L, O'Donovan M, Gay NJ; OCCAMS Consortium, Fitzgerald RC.

PLoS Genet. 2017 May 22;13(5):e1006808. doi: 10.1371/journal.pgen.1006808. eCollection 2017 May.

49.

IRES-Mediated Protein Translation Overcomes Suppression by the p14ARF Tumor Suppressor Protein.

Xi S, Zhao M, Wang S, Ma L, Wang S, Cong X, Gjerset RA, Fitzgerald RC, Huang Y.

J Cancer. 2017 Apr 9;8(6):1082-1088. doi: 10.7150/jca.17457. eCollection 2017.

50.

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Genome Res. 2017 Jun;27(6):902-912. doi: 10.1101/gr.214296.116. Epub 2017 May 2. Erratum in: Genome Res. 2017 Oct;27(10 ):1782.

Supplemental Content

Loading ...
Support Center